Get the Stockscreener App
15.62
2.97%
0.45
After Hours:
15.60
-0.02
-0.13%
Phathom Pharmaceuticals Inc stock is traded at $15.62, with a volume of 765.74K.
It is up +2.97% in the last 24 hours and up +15.36% over the past month.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.
See More
Previous Close:
$15.17
Open:
$15.41
24h Volume:
765.74K
Relative Volume:
0.70
Market Cap:
$1.11B
Revenue:
$114.04M
Net Income/Loss:
$-330.15M
P/E Ratio:
-3.3023
EPS:
-4.73
Net Cash Flow:
$-274.85M
1W Performance:
+4.13%
1M Performance:
+15.36%
6M Performance:
+282.84%
1Y Performance:
+74.14%
1-Day Range:
$15.21
$16.27
1-Week Range:
$14.61
$16.27
52-Week Range:
$2.21
$16.27
Phathom Pharmaceuticals Inc Stock (PHAT) Company Profile
Name
Phathom Pharmaceuticals Inc
Sector
Industry
Phone
(877) 742-8466
Address
100 CAMPUS DRIVE,, FLORHAM PARK, NJ
Compare PHAT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PHAT
Phathom Pharmaceuticals Inc
|
15.62 | 1.08B | 114.04M | -330.15M | -274.85M | -4.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
433.61 | 109.65B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
780.19 | 82.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
451.23 | 58.81B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
911.98 | 56.50B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
207.77 | 43.62B | 447.02M | -1.18B | -906.14M | -6.1812 |
Phathom Pharmaceuticals Inc Stock (PHAT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-14-25 | Initiated | Cantor Fitzgerald | Overweight |
| May-03-24 | Initiated | Stifel | Buy |
| Jan-05-24 | Reiterated | Needham | Buy |
| Aug-09-23 | Initiated | H.C. Wainwright | Buy |
| May-11-23 | Upgrade | Evercore ISI | In-line → Outperform |
| Mar-13-23 | Initiated | Craig Hallum | Buy |
| Oct-21-22 | Initiated | Jefferies | Buy |
| May-06-22 | Downgrade | Evercore ISI | Outperform → In-line |
| May-12-21 | Upgrade | Goldman | Sell → Neutral |
| Feb-17-21 | Initiated | BMO Capital Markets | Outperform |
| Feb-02-21 | Initiated | Guggenheim | Buy |
| Jun-26-20 | Downgrade | Goldman | Neutral → Sell |
| Nov-20-19 | Initiated | Evercore ISI | Outperform |
| Nov-19-19 | Initiated | Goldman | Neutral |
| Nov-19-19 | Initiated | Jefferies | Buy |
| Nov-19-19 | Initiated | Needham | Buy |
View All
Phathom Pharmaceuticals Inc Stock (PHAT) Latest News
Responsive Playbooks and the PHAT Inflection - news.stocktradersdaily.com
Phathom Pharmaceuticals stock hits 52-week high at 16.08 USD By Investing.com - Investing.com Nigeria
Is Phathom Pharmaceuticals Inc a good long term investmentIPO Market Watch & Budget Friendly Capital Growth - earlytimes.in
How Phathom Pharmaceuticals Inc. stock benefits from strong dollarJuly 2025 Earnings & Accurate Intraday Trading Signals - moha.gov.vn
Phathom Pharmaceuticals research links GLP-1 use to higher GERD risk - Traders Union
Phathom Pharmaceuticals Inc. (PHAT) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Phathom Pharmaceuticals: Superior Efficacy Drives Vonoprazan Growth (NASDAQ:PHAT) - Seeking Alpha
What Wall Street predicts for Phathom Pharmaceuticals Inc. stock priceJuly 2025 Macro Moves & Safe Entry Momentum Tips - newser.com
Is Phathom Pharmaceuticals Inc. stock a contrarian buyGap Up & Daily Growth Stock Tips - newser.com
Is Phathom Pharmaceuticals Inc. stock a smart buy before Fed meeting2025 Market Overview & Fast Moving Stock Trade Plans - newser.com
What margin trends mean for Phathom Pharmaceuticals Inc. stockJuly 2025 Summary & Daily Stock Momentum Reports - newser.com
Is Phathom Pharmaceuticals Inc. stock positioned for digital transformation2025 Market Sentiment & Safe Entry Trade Reports - newser.com
Understanding the Setup: (PHAT) and Scalable Risk - news.stocktradersdaily.com
Comparing Phathom Pharmaceuticals Inc. in custom built stock radarsJuly 2025 Momentum & AI Powered Buy and Sell Recommendations - newser.com
Volume spikes in Phathom Pharmaceuticals Inc. stock – what they meanMarket Risk Analysis & Growth Oriented Trade Recommendations - newser.com
Will Phathom Pharmaceuticals Inc. stock reach all time highs in 20252025 Top Decliners & Proven Capital Preservation Methods - newser.com
Volatility clustering patterns for Phathom Pharmaceuticals Inc.July 2025 Review & Capital Efficiency Focused Strategies - newser.com
Why Phathom Pharmaceuticals Inc. stock remains a top recommendationTrade Volume Summary & Stock Market Timing Techniques - newser.com
Is Phathom Pharmaceuticals Inc. stock a buy on dipsGlobal Markets & Community Shared Stock Ideas - newser.com
Can Phathom Pharmaceuticals Inc. recover in the next quarterJuly 2025 Update & Verified Momentum Stock Watchlist - newser.com
Strong Week for Phathom Pharmaceuticals (NASDAQ:PHAT) Shareholders Doesn't Alleviate Pain of Five-year Loss - 富途牛牛
How sentiment analysis helps forecast Phathom Pharmaceuticals Inc. - newser.com
Could Clinical Progress With VOQUEZNA Reshape Phathom Pharmaceuticals’ Long-Term Strategy (PHAT)? - Yahoo Finance
Phathom Pharmaceuticals Inc Stock (PHAT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.45%
1.13%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):